Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eli Lilly and Company
Woman and Man Max 99 years
Eli Lilly and Company (USA)
Update Il y a 4 ans
A phase 3 study to determine the efficacy and safety of recombinant human activated protein C in severe sepsis
Not provided at time of registration
Country
Belgium
,
Canada
,
France
,
Spain
,
United States
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary objective of Part B is to compare the PFS of ramucirumab administered in combination with erlotinib versus placebo in combination with erlotinib in previously untreated patients with EGFR ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Pemetrexed and Cisplatin plus Enzastaurin versus Pemetrexed and Cisplatin plus Placebo in Chemonaive Patients with Advanced, Unresectable, or Metastatic (Stage IIIB or IV) Nonsquamous Non-Small Cell Lung Cancer
The study will be conducted in 2 parts: • Part 1: a single-arm, unblinded, safety lead in. • Part 2: a multiple-site, randomized, double-blind, placebo-controlled study. The objective of the Safety l...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
The Effect of Postprandial Hyperglycemia on Arterial Stiffness in Patients with Type 2 Diabetes
to examine in T2DM patients whether pulse wave velocity (PWV) differs between postprandial hyperglycemia and nearly normal postprandial glycemia, and whether microalbuminuria influences the outcome of...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome
to assess the efficacy of duloxetine 60/120mg once daily (QD) compared with placebo on the treatment of pain in patients with American College of Rheumatology (ACR) defined primary fibromyalgia syndro...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancer
To characterize further the safety profile of the combination of abemaciclib and pembrolizumab
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Study of Soft Tissue Sarcoma with Olaratumab, Gemcitabine and Docetaxel
Overall Survival (OS)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Home Delivery of Pemetrexed : A Feasibility Study
To assess the adherence rate to pemetrexed administered in a domiciliary setting.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A study of blood pressure and pulse rate in type 2 diabetes mellitus
The primary objective of this study is to demonstrate that the change from baseline in mean 24 hour systolic blood pressure of LY2409021 20 mg is noninferior to placebo at 6 weeks, as measured by ABPM...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Phase 3 Study in Moderate to Severe Psoriasis Patients
Efficacy of ixekizumab in subjects with moderate to severe chronic plaque psoriasis based on sPGA and PASI at 12 weeks
Country
None
organs
None
Specialty
None
unknown
More information
Previous
6
7
8
9
10
11
12
13
14
15
Next